Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Study to Assess the Pharmacokinetics of Intravenous Nabi 5% Hepatitis B Immune Globulin Used in Combination With Lamivudine

NCT01421212 is registered in ClinicalTrials.gov with Biotest Pharmaceuticals Corporation as lead sponsor.

NCT NCT01421212
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01421212 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Study to Assess the Pharmacokinetics of Intravenous Nabi 5% Hepatitis B Immune Globulin Used in Combination With Lamivudine
Lead sponsor
Biotest Pharmaceuticals Corporation
Phase
Phase 1/2
Overall status
Completed
Start date
November 30, 1999
Completion date
February 28, 2002
Enrollment
30 (actual)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

hepatitis b virus associated liver disease